Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | TYMS | P04818 | 4/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MPI | P34949 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL76490 | 0.73 | ALDH1A1 (0.58) | ALDH1A1MCL1CES2BCHECES1 | |
| Acenaphthoquinone SCHEMBL141538 | 0.67 | ALDH1A1 (1.00) | ALDH1A1MCL1CES2BCHECES1 | |
| Acenaphthoquinone SCHEMBL29586645 | 0.67 | ALDH1A1 (1.00) | ALDH1A1MCL1CES2BCHECES1 | |
| SCHEMBL18803237 | 0.67 | ALDH1A1 (0.89) | ALDH1A1MCL1CES2BCHECES1 | |
| Acenaphthoquinone SCHEMBL2156555 | 0.67 | ALDH1A1 (1.00) | ALDH1A1MCL1CES2BCHECES1 | |
| SCHEMBL1266199 | 0.66 | ALDH1A1 (0.61) | ALDH1A1MCL1CES2BCHECES1 | |
| Acenaphthoquinone SCHEMBL10628576 | 0.65 | ALDH1A1 (0.94) | ALDH1A1MCL1CES2BCHECES1 | |
| Acenaphthoquinone SCHEMBL28105137 | 0.65 | ALDH1A1 (0.94) | ALDH1A1MCL1CES2BCHECES1 | |
| Acenaphthoquinone SCHEMBL10628581 | 0.65 | ALDH1A1 (0.94) | ALDH1A1MCL1CES2BCHECES1 | |
| SCHEMBL4612919 | 0.65 | ALDH1A1 (0.94) | ALDH1A1MCL1CES2BCHECES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2021-11-09 | — | — | US | disclosed |
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2017-08-17 | — | — | US | disclosed |
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | DALIAN UNIVERSITY OF TECHNOLOGY (CN) | 2011-10-13 | — | — | US | disclosed |
| CN-101633637-B | 8-oxo-8H-acenaphtho[1,2-b]pyrrole derivative | UNIV EAST CHINA SCIENCE & TECH | 2011-09-28 | — | — | CN | disclosed |
| CN-101633637-B | 8-oxo-8H-acenaphtho[1,2-b]pyrrole derivative | UNIV EAST CHINA SCIENCE & TECH | 2011-09-28 | — | — | CN | disclosed |
| CN-101633637-A | 8-oxo-8H-acenaphtho[1,2-b]pyrrole derivative | UNIV EAST CHINA SCIENCE & TECH | 2010-01-27 | — | — | CN | disclosed |
| CN-101633637-A | 8-oxo-8H-acenaphtho[1,2-b]pyrrole derivative | UNIV EAST CHINA SCIENCE & TECH | 2010-01-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231986-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | ALDH1A1 4519/4885MCL1 30/4885CES2 3320/4885 |
| US-11166951-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | ALDH1A1 4519/4885MCL1 30/4885CES2 3320/4885 |
| US-20110251188-A1 | ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF | BID, BCL2, BAX | ALDH1A1 3230/4885MCL1 10/4885CES2 1888/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | ALDH1A1 4519/4885MCL1 30/4885CES2 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.